



Post Authorisation Assessments

Endospec SC 2.5% w/v Oral Suspension Vm 50146/4030

28 October 2025	Submission of a Ph. Eur. CEP for an active substance. Submission of a Ph. Eur. CEP for an active substance. Submission of a Ph. Eur. CEP for an active substance. Submission of a Ph. Eur. CEP for an active substance.
20 November 2024	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
14 June 2023	Change to in-process tests or limits applied during the manufacture of the finished product: - Other changes.
14 June 2023	Deletion of a non-significant in-process test during the manufacture of the finished product.
03 March 2023	Approval of mock ups.
15 November 2022	Replacement of a quality testing site.
14 April 2022	Tightening of specification limits of the immediate packaging of the finished product.
26 January 2021	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.
17 September 2020	Changes to the labelling and/or package leaflet.
21 August 2020	Deletion of manufacturing site responsible for batch release.
23 January 2020	Changes in the qualitative and quantitative composition of the immediate packaging of the finished product.
24 July 2019	Change in the name of a manufacturer used in the manufacture of the active substance. Change in the name and/or address of a manufacturer of the finished product, also responsible for batch release.
19 June 2019	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
25 October 2018	Changes to an existing pharmacovigilance system as described in the DDPS. Change of MAH, from Cross Vetpharm Group Ltd, Broomhill Road, Tallaght, Dublin 24, Ireland to Bimeda Animal Health Limited, 2 / 3 / 4 Airton Close, Tallaght, Dublin 24, Ireland.
10 July 2018	Change in specifications from a national pharmacopoeia of a Member State to the Ph. Eur.
15 January 2018	Increase in the shelf-life of the finished product after first opening to 6 months.
19 May 2017	Change in the number of units in a pack within the range of the currently approved pack sizes of the finished product Deletion of a pack sizes of the finished product. Changes in the qualitative and quantitative composition of the immediate packaging of the finished product Change in shape or dimensions of the container or closure

	(immediate packaging)
12 April 2017	Submission of an updated Ph. Eur. certificate of suitability.
21 October 2016	Change in pack size of the finished product. Change of a measuring or administration device.
13 July 2016	Increase in the batch size. Change in the manufacturing process of the finished product
02 February 2016	Change in shape or dimensions of the container or closure (immediate packaging). Change in the specification parameters and/or limits of the immediate packaging of the finished product.
04 February 2015	Updates to the product literature.
16 December 2014	Submission of an updated Ph. Eur. Certificate of Suitability for the active substance.
10 March 2014	Change in the specification parameters of the finished product.
27 July 2011	Change in specification of the finished product
19 May 2011	Removal of a manufacturer of the active substance Submission of a new Ph. Eur. Certificate of Suitability for an active substance
23 June 2010	Addition of a statement regarding mixing with other products on the Product Literature
06 August 2008	Change of legal category from PML to POM-VPS Changes to the SPC and Product Literature to bring in line with new legislation
14 December 2007	Change of name of manufacturer of the active substance
13 February 2006	Renewal
14 March 2003	Change in specification of the finished product
16 August 2002	Additional pack sizes – 1L, 2.5L and 5L backpacks
20 November 2001	Renewal
25 November 1998	Change of manufacturer of the active substance
09 December 1996	Change of formulation Change of product name from 'Endospec 2.5%' to 'Endospec SC 2.5% w/v Oral Suspension'